{"id":"W4317989607","doi":"10.1182/bloodadvances.2022009389","title":"Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL coexpressing BCL2 and MYC in the phase 3 PHOENIX trial","year":2023,"lang":"en","type":"article","venue":"Blood Advances","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia","funders":"H. Lundbeck A/S; Incyte; Teva Pharmaceutical Industries; Genentech; Celgene; University of Southampton; Karyopharm Therapeutics; Kite Pharma; Gilead Sciences; Bristol-Myers Squibb; TG Therapeutics; Amgen","keywords":"Ibrutinib; Medicine; Oncology; Internal medicine; CHOP; Clinical trial; Bruton's tyrosine kinase; Phases of clinical research; Immunology; Lymphoma; Cancer research; Leukemia; Receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001880478,0.0006793462,0.001107943,0.0002015196,0.0002385306,0.0009869542,0.0004559713,0.0005605198,0.001598611],"category_scores_gemma":[0.001129809,0.0002085957,0.0008304983,0.0002913856,0.0003266528,0.0006592523,0.0003287246,0.001665474,0.0002856181],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006985705,"about_ca_system_score_gemma":0.000425436,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005796893,"about_ca_topic_score_gemma":0.001539036,"domain_scores_codex":[0.9994592,0.0003391305,0.00002144828,0.00006091105,0.00003923703,0.00008015063],"domain_scores_gemma":[0.9995539,0.0001255523,0.0001026076,0.0000299808,0.00002639058,0.0001616388],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7741846,0.007027691,0.01420451,0.0008318021,0.002461638,0.0003249602,0.0002980863,0.004301144,0.02095781,0.00035878,0.005648514,0.1694004],"study_design_scores_gemma":[0.6070389,0.289677,0.07984535,0.0002676353,0.001998354,0.0008451099,0.0002186892,0.005071266,0.004205471,0.0008439091,0.009917517,0.00007088412],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9919926,0.004673394,0.00016805,0.0004144407,0.00008353357,0.0003272681,0.0005426893,0.00004175283,0.001756285],"genre_scores_gemma":[0.9934576,0.00222911,0.0004507188,0.000685549,0.0000923695,0.0002975359,0.001666443,0.00001643391,0.001104261],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001880478,"threshold_uncertainty_score":0.009945035,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07110328231378076,"score_gpt":0.4849904588907227,"score_spread":0.413887176576942,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}